ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 Press release … Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, Netherlands & CAMBRIDGE, Mass., April … April 13, 2021
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release … 2/3 Illuminate trial of sepofarsen for CEP290 -mediated Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation, also … January 04, 2022
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO) Press release … trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, … November 02, 2020
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Press release … call on July 20, 2020 at 5:00 pm EDT, which will focus on Leber congenital amaurosis 10 (LCA10) and the investigational RNA therapy for … July 13, 2020
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Press release … trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … October 10, 2019
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Press release … analysis of its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … September 05, 2018
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Press release … Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Key Updates ProQR receives Fast Track … May 31, 2017
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO) Press release … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … June 08, 2020
ProQR Therapeutics Announces Results for the First Quarter of 2015 Press release … treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced results for the first quarter of … May 21, 2015
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release … of CEP290-associated inherited retinal disease called Leber congenital amaurosis (LCA10): A randomized, double-masked, … April 26, 2022